Ketorolac
DrugKetorolac was administered intravenously: 30 mg in the operating room, and 15 mg every 6 hours for 7 doses post-operatively.
Other names: Toradol
NCT Number: NCT03669081
The investigators will assess how the use of toradol and pregabalin affects return to bowel function and see if there is a difference in length of hospital stay. Narcotic use can affect bowel function so the investigators hypothesize that use of Toradol will decrease delayed bowel function and aid in a patients discharge and reduction of hospital stay.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 2
Perioperative pain management is a significant challenge following surgery. Many pathways contribute to perioperative pain, including nociceptive, inflammatory, and neuropathic sources. Although opioids have long been a mainstay for perioperative analgesia, other non-opioid therapies have been increasingly used as part of a multimodal analgesic regimen to provide improved pain control while minimizing opioid-related side effects
TORADOL (ketorolac tromethamine), is a nonsteroidal anti-inflammatory drug (NSAID), is indicated for the short-term (up to 5 days in adults), management of moderately severe acute pain that requires analgesia at the opioid level.
Anecdotal evidence has shown that the use of Toradol (Ketorolac) is safe in renal surgery patients. The study team aims to further evaluate this in a pilot study specifically in the population of patient who have donated their kidney in live kidney transplants. The study team will assess how the use of toradol affects return to bowel function and see if there is a difference in length of hospital stay. Narcotic use can affect bowel function so the investigators hypothesize that use of Toradol will decrease delayed bowel function and aid in a patients discharge and reduction of hospital stay. The study team will assess differences in visual analog pain scores and total narcotic consumption, whereas secondary endpoints of urine output, serum creatinine and hemoglobin levels to assess for efficacy and safety.
Pregabalin is prescribed for neuropathic pain. In many studies, preoperative administration of pregabalin reduced postoperative morphine consumption and early postoperative pain.
There will be two arms of the study including:
Arm 1 (pure placebo group): Placebo oral preop then Saline placebo IV x 1 in the OR, then saline placebo IV every 6 hours for 7 doses.
Arm 2: Pregabalin 75mg oral preop, then Ketorolac 30 mg IV x 1 in the OR, then ketorolac 15 mg IV every 6 hours for 7 doses.
Toradol and Lyrica will be used consistent with its FDA approval in terms of dosing, route of administration, etc.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Ketorolac was administered intravenously: 30 mg in the operating room, and 15 mg every 6 hours for 7 doses post-operatively.
Other names: Toradol
Pregabalin was administered orally: 75 mg 30 minutes prior to operation.
Other names: Lyrica
Placebo oral capsule was administered orally 30 minutes prior to operation.
Saline was administered intravenously: once in the operating room, and every 6 hours for 7 doses post-operatively.
Time frame: 82.25 hours
Cumulative narcotic use was defined by cumulative morphine equivalents over the course of a patient's hospital course. The Washington State Agency Medical Director's Group Opioid dose calculator was used to provide a total morphine dose equivalent (MDE) for each patient while in the hospital.
Time frame: 82.25 hours
Primary outcomes include length of hospital stay (LOS).
Time frame: 1 year
Renal function was evaluated by following serum creatinine levels for up to one year post-operatively.
Time frame: 24 hours
Hematocrit levels were evaluated post-operatively for up to a day post-operatively for signs of blood loss.
Time frame: 82.25 hours
Patients were evaluated post-operatively during hospital stay for instances of urinary retention.
Time frame: 30 days
Primary outcomes include 30 day mortality post-operatively.
University of Utah
Other
A Prospective, Double-blind, Randomized Pilot Study Evaluating the Effects of Toradol and Lyrica Verses Placebo for Pain Control After Donor Nephrectomy (TORPEDO)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05283980
Acute Pain, Behavior
Boston, Massachusetts, United States
View Trial DetailsNCT05859061
Neurologic Manifestations, Pain
Chicago, Illinois, United States
View Trial DetailsNCT06791577
Blood Coagulation Disorders, Bruising
São Paulo, Brazil
View Trial DetailsNCT03090776
Neurologic Manifestations, Pain
Boston, Massachusetts, United States
View Trial Details